Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
about
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaCOEXPEDIA: exploring biomedical hypotheses via co-expressions associated with medical subject headings (MeSH)Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.Circulating miRNA markers show promise as new prognosticators for multiple myeloma.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.European perspective on multiple myeloma treatment strategies: update following recent congressesProteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markersThe use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.Risk stratification in Waldenström macroglobulinemia.Investigational drugs for coagulation disorders.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Current Review on High-Risk Multiple Myeloma.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple MyelomaIn non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival.Prospective nested case-control study of feature genes related to leukemic evolution of myelodysplastic syndrome.
P2860
Q28296718-F6C65C2F-D24B-4946-B066-4CCFC9EC7444Q28818101-998D1605-93F5-4361-9175-33C4B3181C1EQ33655234-6998E6B2-10CC-48F4-A993-168C9FECBB5FQ34135498-96708B67-C5E8-4C1B-935E-D8B63648314AQ34773850-536F9B62-001D-4346-A3EF-C73D49A52A68Q35849219-27A81449-1FDF-4B00-B05D-5EC795B165C1Q35989943-2B83180F-EFD5-45E1-BFF0-2B661F9F3247Q36665156-C3AE7EB6-37B6-4192-B500-66E7A8724C3EQ37946246-4E0314FA-64E0-464D-9A31-0C8EFDB52EB4Q37999886-909941AF-BE2D-4C1F-A66C-695973D6789AQ38106245-DCFA304A-A280-4535-9C7B-D1BB33972299Q38462720-05B3BE04-DACC-497F-A51D-D958661659B1Q38895167-A8EA3F64-D665-442E-880B-7EFB90CE6AC7Q39177792-543EBFA9-6DDE-438C-940B-2004716A3967Q42055422-F0AE5078-37F9-4817-A9B8-92473828DC0EQ42212863-91B5A8CF-5F0E-4ABA-AC29-530F63FCFA36Q45332140-609C110E-86CE-4D45-BB2E-BE38446029F3
P2860
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Impact of gene expression prof ...... lenalidomide and dexamethasone
@ast
Impact of gene expression prof ...... lenalidomide and dexamethasone
@en
type
label
Impact of gene expression prof ...... lenalidomide and dexamethasone
@ast
Impact of gene expression prof ...... lenalidomide and dexamethasone
@en
prefLabel
Impact of gene expression prof ...... lenalidomide and dexamethasone
@ast
Impact of gene expression prof ...... lenalidomide and dexamethasone
@en
P2093
P2860
P1433
P1476
Impact of gene expression prof ...... lenalidomide and dexamethasone
@en
P2093
David S Siegel
Greg J Ahmann
Hajime Uno
Jessica L Haug
Kimberly J Henderson
Natalie S Callander
Philip R Greipp
Rafael Fonseca
Scott A Van Wier
Shaji K Kumar
P2860
P304
P356
10.1182/BLOOD-2011-03-342089
P407
P577
2011-08-22T00:00:00Z